More importantly, said he and Amgen attorney Robert Sacks, Micromet reached out to seven pharmaceutical companies, none of which showed interest in making a competitive bid. Parsons also concluded that the sale process leading up to the deal was reasonable, and that the board was sufficiently independent to approve the deal. Amgen's tender offer of $11 per share expired at midnight Thursday, heightening the urgency of resolving the Delaware case. In a statement today, Amgen said all outstanding conditions were satisfied, allowing it to proceed with its planned acquisition of all outstanding shares of Micromet common stock by a wholly owned subsidiary. Amgen said approximately 80,025,097 Micromet shares representing about 83.95% of the company's outstanding shares were validly tendered and not withdrawn, with another approximately 3,150,586 additional Micromet shares tendered by guaranteed delivery. Amgen also said it launched a subsequent offering period set to expire at midnight March 6.